Survey Finds Asian Americans Are Racial Or Ethnic Group Most Willing To Get Vaccine

May have missed it but have not seen any comparable data for Canada:

A wide-ranging survey shows Americans’ willingness to receive a coronavirus vaccine when it becomes publicly available and confidence in its effectiveness are on the rise.

But when broken down by racial or ethnic group, Black respondents show the most reluctance, with less than half saying they will do so.

The survey by the Pew Research Center found that 60% of Americans overall say they would definitely or probably get a vaccine for the coronavirus if it were available today.

While that figure is 9% higher than it was in September, it still lags behind the 72% of Americans who said in May they would get the vaccine, when clinical trials for a vaccine were just getting underway.

Roughly four in 10 respondents overall (39%) say they would definitely not or probably not get a vaccine, according to Pew.

However, about half of that cohort did leave open the possibility they could change their mind once more information is available and once others get vaccinated. The other half said they are “pretty certain” more information will not change their decision.

Pew found quite a bit of variance when responses were broken down by racial or ethnic group on willingness to get a vaccine.

A whopping 83% of “English-speaking Asian Americans…say they would definitely or probably get vaccinated,” outpacing all other racial or ethnic groups, according to Pew.

White and Latinx respondents answered about the same, with 63% and 61% respectively saying they definitely or probably would get the vaccine.

“Black Americans continue to stand out as less inclined to get vaccinated than other racial and ethnic groups,” according to Pew, which found that just 42% of African Americans said they would get one when made publicly available.

This figure may be surprising to some, given that 71% of Black respondents told researchers they knew someone who has died or been hospitalized due to the virus, nearly 20 points higher than Americans overall (54%).

But there is a long history of mistrust on the part of Black Americans toward public health officials, much of it stemming from the notorious Tuskegee experiment of the 1930s, when researchers lied to hundreds of Black men, telling them they were conducting research on treatments for “bad blood.”

In reality the scientists were allowing the Black men to die of untreated syphilis. Those experiments were slated to go on for six months, but they lasted 40 years, according to the Centers for Disease Control and Prevention.

That is perhaps why Barack Obama, the nation’s first Black president, said in an interview this week with SiriusXM’s The Joe Madison Show that he’d be willing to get vaccinated in front of cameras when it becomes available.

“I promise you that when it’s been made for people who are less at risk, I will be taking it,” Obama said. “I may end up taking it on TV or having it filmed, just so that people know that I trust this science.”

Former presidents Bill Clinton and George W. Bush have also said they are willing to get the vaccine in front of a camera.

The Pew study was a national survey conducted between Nov. 18 and Nov. 29 surveying 12,648 U.S. adults.

The margin of sampling error for the survey is plus or minus 1.5 percentage points.

Source: Survey Finds Asian Americans Are Racial Or Ethnic Group Most Willing To Get Vaccine

Germany tries to halt U.S. interest in firm working on coronavirus vaccine

Pretty reprehensible actions if true (in line with the America first rhetoric):

Berlin is trying to stop Washington from persuading a German company seeking a coronavirus vaccine to move its research to the United States, prompting German politicians to insist no country should have a monopoly on any future vaccine.

German government sources told Reuters on Sunday that the U.S. administration was looking into how it could gain access to a potential vaccine being developed by a German firm, CureVac.

Earlier, the Welt am Sonntag German newspaper reported that U.S. President Donald Trump had offered funds to lure CureVac to the United States, and the German government was making counter-offers to tempt it to stay.

Responding to the report, the U.S. ambassador to Germany, Richard Grenell, wrote on Twitter: “The Welt story was wrong.”

A U.S. official said: “This story is wildly overplayed … We will continue to talk to any company that claims to be able to help. And any solution found would be shared with the world.”

A German Health Ministry spokeswoman, confirming a quote in the newspaper, said: “The German government is very interested in ensuring that vaccines and active substances against the new coronavirus are also developed in Germany and Europe.”

“In this regard, the government is in intensive exchange with the company CureVac,” she added.

Welt am Sonntag quoted an unidentified German government source as saying Trump was trying to secure the scientists’ work exclusively, and would do anything to get a vaccine for the United States, “but only for the United States.”

German Interior Minister Horst Seehofer told a news conference that the government’s coronavirus crisis committee would discuss the CureVac case on Monday.

CureVac issued a statement on Sunday, in which it said: “The company rejects current rumors of an acquisition”.

CureVac’s main investor Dietmar Hopp said he was not selling and wanted CureVac to develop a coronavirus vaccine to “help people not just regionally but in solidarity across the world.”

“I would be glad if this could be achieved through my long-term investments out of Germany,” he added.

A German Economy Ministry spokeswoman said Berlin “has a great interest” in producing vaccines in Germany and Europe.

She cited Germany’s foreign trade law, under which Berlin can examine takeover bids from non-EU, so-called third countries “if national or European security interests are at stake”.

EXPERIMENTAL VACCINE

Florian von der Muelbe, CureVac’s chief production officer and co-founder, told Reuters last week the company had started with a multitude of coronavirus vaccine candidates and was now selecting the two best to go into clinical trials.

The privately-held company based in Tuebingen, Germany hopes to have an experimental vaccine ready by June or July to then seek the go-ahead from regulators for testing on humans.

On its website, CureVac said CEO Daniel Menichella early this month met Trump, Vice President Mike Pence, members of the White House Coronavirus Task Force and senior representatives of pharmaceutical and biotech companies to discuss a vaccine.

CureVac in 2015 and 2018 secured financial backing for development projects from its investor the Bill & Melinda Gates Foundation, working on shots to prevent malaria and influenza.

In the field of so-called mRNA therapeutics, CureVac competes with U.S. biotech firm Moderna and German rival BioNTech, which Pfizer (PFE.N) has identified as a potential collaboration partner.

Drugs based on mRNA provide a type of genetic blueprint that can be injected into the body to instruct cells to produce the desired therapeutic proteins. That contrasts with the conventional approach of making these proteins in labs and bio-reactors.

In the case of vaccines, the mRNA prompts body cells to produce so-called antigens, the tell-tale molecules on the surface of viruses, that spur the immune system into action.

Companies working on other coronavirus-vaccine approaches include Johnson & Johnson (JNJ.N) and INOVIO Pharmaceuticals, Inc. (INO.O).

Source:  Germany tries to stop U.S. from luring away firm seeking coronavirus vaccine